# SynRx Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/synrx-therapeutics

- Industry: Biotechnology
- Headquarters: Hangzhou, China
- Website: www.synrx.cn/
- Latest round: Series A (Dec 8, 2025)
- Investors on record: 6

## About

Established in 2021 and based in Hangzhou, China, Hangzhou SynRx Therapeutics Co., Ltd., trading as SynRx Therapeutics, develops innovative oncology therapeutics focused on DNA damage repair pathways. The company was founded by Professor Yu Xiaochun, a faculty member of Westlake University and the University of Michigan, who has published over 100 academic papers and patents. SynRx has expanded operations with an additional site in Shanghai and has advanced multiple first-in-class small molecule drug candidates into preclinical and early clinical development. In December 2025, the firm closed a series A funding round led by ZJ Biomedicine and High-end Equipment Industry Fund.

The company develops small molecule drug candidates targeting DNA damage repair mechanisms for oncology indications. Its pipeline includes preclinical and clinical stage programs designed for homologous recombination repair deficient solid tumors and other malignancies. Drug candidates under development include SY001, SY002, SY003, SY004 and SY005, which are evaluated for application in late stage clinical cancer treatment.

The company’s revenue model includes research collaborations, licensing agreements with development and commercialization of its drug candidates.

The company plans to use the series A funding to accelerate the clinical development of its core drug candidates SYN818 and SYN608 and to further advance its R&D platform in the DNA damage repair DDR therapeutic field.

## Funding rounds

- Series A, Dec 8, 2025 — Haibang Venture, Lapam Capital, HangZhou Capital, Liyao Medicine, ZJ Biomedicine and High-end Equipment Industry Fund
- Angel, Dec 21, 2021 — Haibang Venture, Yantong Investment

## Investors

- Haibang Venture — Angel, Series A
- Yantong Investment — Angel
- Lapam Capital (https://capitalatlas.ai/funds/lapam-capital) — Series A
- HangZhou Capital (https://capitalatlas.ai/funds/hangzhou-capital) — Series A
- Liyao Medicine — Series A
- ZJ Biomedicine and High-end Equipment Industry Fund — Series A